The bicyclic nucleoside analogue (BCNA) Cf1743 and its orally bioavailable prodrug FV-100 have unique potential as varicella-zoster virus (VZV) inhibitors to treat herpes zoster (shingles) and the therewith associated pain, including post-herpetic neuralgia (PHN). The anti-VZV activity of Cf1743 depends on a specific phosphorylation by the VZV-encoded thymidine kinase (TK). The target of antiviral action is assumed to be the viral DNA polymerase (or DNA synthesis in the virus-infected cells).
All Keywords
【저자키워드】 Varicella-zoster virus., herpes zoster, DNA polymerase, thymidine kinase, Cf1743, FV-100,
【저자키워드】 Varicella-zoster virus., herpes zoster, DNA polymerase, thymidine kinase, Cf1743, FV-100,